The impact of activating KIR (aKIR) and inhibitory KIR (iKIR) on OS, relapse-related mortality (RRM) and acute GVHD (aGVHD) was prospectively studied in 84 adults with high-risk hematologic malignancies receiving reduced intensity conditioning (RIC) T-cell depleted hematopoietic SCT (HSCT) from haploidentical related donors. In this clinical model, freedom from RRM is dependent on GVL effect. Patients were divided into myeloid (n ¼ 49) and lymphoid (n ¼ 35) malignancy groups. KIR-ligand and ligand-ligand models were studied in both GVH and rejection directions and statistically correlated with outcome measures. In the myeloid group, OS was higher (P ¼ 0.009) and RRM was lower (P ¼ 0.036) in patients missing HLA-C group2 ligand to donor iKIR. OS was higher if patients had 41 missing ligand (P ¼ 0.018). In lymphoid malignancy, missing ligand to donor KIR had no impact on OS or RRM. However, OS was better with donor aKIR 2DS2 (P ¼ 0.028). There was a trend towards shorter OS in recipient with KIR 2DS1, 2DS5 and 3DS1, although sample sizes were too small to provide inferential statistics. Findings in lymphoid malignancy patients should be further studied. These results suggest that the absence of appropriate HLA ligands in the recipient to donor iKIR may induce GVL without aGVHD in myeloid malignancy patients undergoing TCD-RIC transplants.
Introduction
The benefit of natural killer (NK) cell mediated GVL effect in haploidentical T-cell-depleted hematopoietic SCT (HSCT) was initially reported after a myeloablative conditioning regimen. 1 However, many patients, particularly those of older age and with co-morbidities are unable to tolerate myeloablative conditioning. Use of reduced intensity conditioning (RIC) allows them to access HSCT. Since GVL is largely responsible for anti-leukemic benefits of RIC transplants, this model is well suited for the study of factors like KIR that may influence the GVL effect. 5 The KIR gene family currently consists of inhibitory KIRs (iKIRs) (KIR 2DL1, KIR 2DL2, KIR 2DL3, KIR 2DL4, KIR 2DL5A, KIR 2DL5B, KIR 3DL1, KIR 3DL2 and KIR 3DL3) and activating KIRs (aKIRs) (KIR 2DS1, KIR 2DS2, KIR 2DS3, KIR 2DS4, KIR 2DS5 and KIR 3DS1) which are located on chromosome 19 and encode for corresponding receptors on NK cells. 6 KIR 2DL1 recognizes HLA-C alleles of the 'C2 group' with Lys at position 80 (HLA-C Lys80 ), KIR 2DL2/3 recognizes HLA-C alleles of the 'C1 group' with Asn at position 80 (HLA-C Asn80 ), KIR 3DL1 recognizes 'Bw4' alleles, and KIR 3DL2 recognizes HLA-A3 and HLA-A11 alleles. [7] [8] [9] It is important to remember that not all KIR genes from an individual's genotype may be expressed nor will all NK cells in that individual carry the corresponding KIR protein on the cell surface. Inhibitory receptors inhibit lysis upon binding the corresponding ligand while stimulation of aKIRs leads to killing by the NK cells. 10 In normal individuals, aKIRs and iKIRs mediate killing of virally infected or tumor cells through corresponding signals upon interactions with specific class I HLA molecules that act as their cognate ligands. 11 Following HSCT, donor-derived NK cells attack allogeneic cells in the patient if the recipient HLA class I ligands do not sufficiently engage their inhibitory receptors. 12 Reduced intensity cytoreduction is expected to spare many host derived immune cells and may allow an anti-graft attack by host NK cells if alloreactivity is present in the reverse direction. HLA ligands for aKIRs are not yet defined but KIR 2DS1 recognizes the C2 group of alleles in EBV-transformed B-lymphocytes 13, 14 and leukemia cells. 12 The current study examines the differences in OS, relapserelated mortality (RRM) and incidence of Grade II-IV acute GVHD (aGVHD) following TCD haploidentical RIC HSCT in patients with lymphoid and myeloid malignancies with respect to the impact of iKIR and aKIRs in the patients and their donors, ligand to ligand mismatch as well as iKIR to ligand alloreactivity in GVH and rejection directions.
Methods
Patient, donor and graft characteristics Between March 2000 and July 2008, 84 consecutive adult patients with relapsed or refractory hematologic malignancies treated at Duke University Medical Center with T-cell depleted PBSC-transplantation from haploidentical related donors following a RIC regimen were included in this prospective study. Donor and patient DNA samples had to be available to be included in the study. All patients lacked suitable related or unrelated BM donors as well as suitable single cord blood units, or they were not eligible for ablative therapy due to age or co-morbidities. All patients were enrolled in IRB approved protocols and had signed informed consent. Diagnoses are shown in Table 1 . The patient and donor pairs were 3/6 (n ¼ 41), 4/6 (n ¼ 29), 5/6 (n ¼ 12) or 6/6 (n ¼ 2). HLA-C and -DQB1 revealed further mismatches. The distribution of HLA matching was similar between the myeloid and lymphoid malignancy patients by Yates Chi-square test. Patients were categorized as having lymphoid (n ¼ 35) or myeloid (n ¼ 49) malignancy (Table 1) . The median age was 48.5 years (range, 18-72 years). Myeloid patients were older (51 vs 43 years; P ¼ 0.032). In general, the patients were heavily pretreated with multiple regimens. A proportion had undergone prior autologous (n ¼ 14; 16.5%) or allogeneic (n ¼ 10; 11.7%) transplants. Fifty-one percent (n ¼ 43) had relapsed or refractory disease at the time of transplant. There was no statistical difference between the myeloid and the lymphoid groups with respect to the prior transplantation and advanced disease status. These characteristics were similar to those reported in a previous paper from our center that focused on the clinical and immunological recovery in a subgroup of these patients. 4 The median duration of follow-up for the whole group and two subgroups are shown in Table 1 . The median follow up for surviving patients was 30.4 months (range, 13-77 months). The patient-donor sex matching was similar between the lymphoid and the myeloid groups.
Donors received filgrastim 8 mg/kg twice daily starting 5 days before pheresis and continuing until apheresis was completed. All purging was accomplished in vivo after stem cell infusion into the patient. In vitro estimation of the degree of T-cell purging was performed in a subset of patients. A 5 mL aliquot of patient serum and pheresed donor cells were mixed into a cell suspension containing 25% serum by volume and incubated for 30 minutes at 37 1C with 2 mg of alemtuzumab followed by a flow analysis for viability of the cellular suspension using the 7-aminoactinomycin-D method. 15, 16 Donor lymphocyte infusions were planned for all patients who had the persistence of disease after transplantation, if they did not have severe GVHD. Details of cell collection, in vivo T-cell depletion, estimates of CD34 þ and CD3 þ cell counts, other graft characteristics, clinical protocol and outcomes on partial cohort is described previously. HLA and KIR typing HLA-A, -B, -C, -DRB1 and -DQB1 were performed on each recipient and donor by reversed Sequence-Specific Oligonucleotide Probe (rSSOP, Luminex), Sequence-Specific Primer, or Sequence-Based Typing. High resolution HLA-C typing was performed retrospectively by SequenceBased Typing when necessary to characterize alleles in the different HLA-C ligand groups. Low resolution KIR typing was performed by using Luminex-rSSOP reagents 
The presence of an epitope of HLA ligand for KIR in the donor and its absence in the patient is assumed to represent potential for donor NK alloreactivity against the patient target cells resulting in alloreactivity in the GVH direction. Conversely, the presence of an epitope of HLA ligand for KIR in the patient and its absence in the donor will result in alloreactivity in the rejection direction. In this study, KIR alloreactivity was measured for HLA-C group one and two, and Bw4 ligand incompatibilities. Each recipient/donor pair was evaluated for L-L incompatibility in both directions. A combined ligand incompatible score was also considered. A positive combined score was assigned when either one or both of HLA-C and -Bw4 ligands were incompatible.
Receptor-ligand Model (Missing Ligand Model).
We measured KIR alloreactivity for missing HLA-C groups one (C1) and two (C2), -Bw4 and/or -A3/11 ligands. Each pair was evaluated for the donor KIR genotype and the lack of corresponding ligands in recipient or vice versa. A combined KIR score was also considered. The combined score was the sum of the number of the KIR genes (2DL1/2/3, 3DL1/2) without ligand.
aKIR receptors. Genotyping was performed for the presence of each aKIR receptor (2DS1, 2DS2, 2DS3, 2DS4, 2DS5 and 3DS1) in donors and patients.
Statistical analysis
Outcome measures used in this study included OS, RRM and aGVHD. aGVHD was scored in all patients by standard criteria 18 and only grades II-IV were measured for this analysis. The probabilities of aGVHD were displayed using the cumulative-incidence-function method. 19 For aGVHD, patients were evaluable after surviving up to day 14, and death without the event was the competing event while patients were censored on the last day of follow-up. OS was measured from the first day of the transplant to death and censored at the last day of follow-up. RRM was measured from the first day of transplantation to death from relapse or progressive disease, or was censored at the time of death from non relapse cause or date of follow-up for living patients. Kaplan-Meier probability curves 20 were used to analyze OS, RRM and acute grades II-IV GVHD by KIR alloreactivity for myeloid malignancy and lymphoid malignancy groups separately, and then with the two groups combined. The differences between groups were compared using the log-rank statistics. 21 Central tendencies of age and duration of follow-up were compared between myeloid and lymphoid patients using the Wilcoxon Rank-Sum test. Proportions with pre-transplant therapies and relapse or refractory disease at transplant in the myeloid and lymphoid groups were compared using the w 2 -test. All P-values are twosided. Analyses were completed using the SAS system, version 9.2, and R, version 2.1.1.
Results

L-L incompatibility: impact on OS, RRM and aGVHD
In the GVHD/GVL direction, L-L incompatibility for either HLA-C or HLA-Bw4 was present in 24% (n ¼ 12) of myeloid and 48.6% (n ¼ 17) of lymphoid malignancy patients. In the rejection direction, incompatibility for either HLA-C or HLA-Bw4 was seen in 24% (n ¼ 12) of myeloid and 37.1% (n ¼ 13) of lymphoid malignancy patients. Subgroup sample sizes were too small to perform statistical analysis for significant differences in L-L incompatibility on OS, RRM or aGVHD.
Missing recipient ligand for donor's iKIR (receptor-ligand alloreactivity in GVH/GVL direction): impact on OS, RRM and aGVHD Distributions of incompatibilities for HLA-A3/A11, -Bw4, -C1 and -C2 were similar in the myeloid and lymphoid cohorts. In the myeloid cohort, alloreactivity for (i) HLAgroup (C2) was associated with higher OS (P ¼ 0.009: Figure 1b ) as well as lower RRM (P ¼ 0.036: Figure 2b) ; (ii) Bw4 was associated with higher OS (P ¼ 0.047: Figure 1a) ; and (iii) A3/A11 was associated with lower RRM (P ¼ 0.02; Figure 2a) . Furthermore, an increasing number of alloreactivities led to higher OS (P ¼ 0.018 for two or three; P ¼ 0.03 for three categories) as shown in Figures 1c and d . RRM was lower in the presence of incompatibility involving A3/A11 (P ¼ 0.02), C2 (P ¼ 0.036) or combined (P ¼ 0.014) as shown in Figures 2a-c . In contrast, in the lymphoid cohort there was no impact of either individual incompatibility for HLA-A3/ A11, -Bw4, -C1 and -C2 or multiple incompatibilities on OS or RRM, but grades II-IV aGVHD trended lower when donor-recipient pairs with C1 or C2 incompatibility (n ¼ 24; P ¼ 0.011) were analyzed together.
Missing donor ligand for recipient's iKIR (receptor-ligand alloreactivity in rejection direction): impact on OS, RRM and aGVHD
Distribution of alloreactivities for HLA-A3/A11, -Bw4, -C1 and -C2 were similar in the myeloid and lymphoid cohorts. In the myeloid cohort, alloreactivity for Bw4 was associated with higher OS (P ¼ 0.014). There was no impact of individual or combined alloreactivities on OS or RRM in the lymphoid malignancy cohort.
aKIR in patients and donors
Genotyping was performed for aKIR receptors (2DS1, 2DS2, 2DS3, 2DS4, 2DS5 and 3DS1) in donors and patients. However, for the outcome analysis, KIR 2DS4 was excluded because almost all samples were positive for it. The presence or absence of any of the aKIRs in either recipient or donor had no impact on OS, RRM or GVHD in myeloid patients. However, in lymphoid patients, a trend towards higher GVHD probability was observed if donor was positive for aKIR 2DS1 (n ¼ 9; P ¼ 0.031). OS in lymphoid patients tended to be higher if the donor carried aKIR 2DS2 (P ¼ 0.028; n ¼ 16) and lower if the recipient carried aKIR 2DS1 (n ¼ 10; P ¼ 0.011), KIR 2DS5 (n ¼ 9; P ¼ 0.035) or KIR 3DS1 (n ¼ 10; P ¼ 0.011).
Discussion
Despite numerous studies in the last decade investigating the impact of KIR on the outcomes of HSCT, a cohesive, all-encompassing and clear theory with supportive clinical evidence regarding the relevant associations has yet to emerge. These associations have been studied separately in various donor sources including matched sibling and unrelated donors, graft sources including BM, PBSCs and umbilical cord blood, and following various cytoreductive regimens with or without T-cell depletion. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] More recently, cellular and molecular studies have elucidated the complexity of the KIR genes, its ligand interactions and effector responses, and allowed the more recent outcome analyses to incorporate a wider range of variables and models of the donor-host NK cell alloreactivities. 10, 27, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Our study includes patients transplanted at a single center using uniform conditioning, graft source, GVHD prophylaxis, supportive care and follow-up on a prospective basis. In this cohort, a high degree of T-cell depletion created a non-competing environment with a low GVHD and minimal need for additional immunosuppression and thus allowed for a clearer evaluation of donor and recipient NK interactions and effector responses. Post transplantation lymphocytic recovery patterns highlighting relative maintenance of the CD56 þ compartment (including NK cells) relative to the CD4 and CD8 compartments with this type of conditioning regimen have been documented in our previous work. 4 To our knowledge, this is the first single center analysis of iKIR and aKIR genotype and ligand in RIC transplants, a group that is arguably more dependent on GVL for OS and freedom from relapse related mortality.
Receptor-Ligand alloreactivity in the GVL/GVH direction in our cohort revealed the greatest degree of impact on the outcome measures. Absence of recipient ligand for donor iKIR (GVH/GVL direction) impacted OS and RRM in the myeloid patients (Figures 1 and 2) . Alloreactivity involving HLA-C2 was most significant and led to higher OS as well as lower RRM. A functional study by Pende et al. 12 provides evidence that KIR 2DL1 can discriminate between C1 and C2 groups leading to differential lysis of C1 vs C2 allele-expressing leukemia blasts. The additional impact of receptor-ligand alloreactivity in our myeloid patients was reflected in a higher OS in relation to Bw4 and lower RRM in relation to A3/A11. The presence of multiple alloreactivities led to the highest OS and lowest RRM. We also noticed a difference between HLA-C1 and HLA-C2 alleles. Myeloid patients with alloreactivity involving HLA-C1 did not have an advantage in OS and RRM. In fact, C1 alloreactivity resulted in higher grades II-IV aGVHD. Cook et al. 43 showed similar findings in matched sibling transplants if the donor carried aKIR 2DS2. KIR 'L-L' incompatibility did not predict OS, RRM or aGVHD in our study. It has been shown that persistence of T-cells inhibits NK cell alloreactivity. 35 It is unclear if that was a factor in this cohort. Similar to our observations, Gagne et al. 27 did not find L-L analysis to be very useful in predicting survival and relapse following unrelated donor transplants. Overall, our findings support the view that receptor-ligand model alloreactivity (with the exception of HLA-C alleles of group C1) in the GVH/GVL direction in myeloid patients induces a GVL effect without causing GVHD and thus leads to a lower RRM and higher OS.
The lower probability of grades II-IV aGVHD in lymphoid malignancy (n ¼ 24) in the presence of mismatch in the receptor-ligand model is previously unreported and merits further scrutiny. Higher GVHD was reported in the presence of receptor-ligand mismatch in two studies done in myeloablative transplant recipients; one from related haploidentical donors 44 and another using T-cell replete grafts from unrelated donors. 23 In a RIC cord blood transplant study, KIR-ligand alloreactivity resulted in significantly higher rates of grade III-IV aGVHD (42% vs 13%) and TRM (27% vs 12%) with inferior survival (32% vs 52%). 24 A recent study provides compelling evidence that the expression of mature KIR repertoires is affected by T-cells in the graft which in turn impacts clinical outcomes after unrelated transplantation. 35 In that context, it is noteworthy that we observed some impact of aKIR in this study. It is important to keep in mind that the conditioning regimen, GVHD prophylaxis, T-cell dose and infused NK cells, graft sizes and T-cell depletion protocols will differ between studies and institutions and may be impacting NK mediated effects. Additionally, in lymphoid patients, a higher GVHD probability was seen if the donor was positive for aKIR 2DS1. OS in lymphoid patients was higher if the donor carried aKIR 2DS2 and lower if the recipient carried aKIR 2DS1, KIR 2DS5 or KIR 2DS1. These findings must be interpreted cautiously because of small numbers and further explored in larger patient populations. Interestingly, Pende et al. 12 showed that leukemic blasts expressing C2/C2 ligands were killed by KIR 2DL2/3 þ NK cells that co-expressed KIR 2DS1 because aKIR 2DS1 could directly recognize C2 on leukemia cells. In the large study of 1087 patients transplanted using unrelated donors through NMDP, recipients of KIR 3DS1 positive donors had lower grade II-IV acute GVHD but no impact on relapse. 29 In conclusion, absence of appropriate HLA ligands in the recipient to donor iKIR may induce GVL without aGVHD in myeloid malignancy patients undergoing haploidentical T-cell depleted RIC transplant from haploidentical related donor. Similar alloreactivity in lymphoid malignancy patients did not have a GVL effect although impact on aGVHD was noted. Cumulative evidence from all previous studies and the current study points to the level of uniqueness of NK mediated effects in specific contexts and suggests that clinical applicability of NK incompatibility must be determined and utilized separately for specific donor sources, conditioning regimens, levels of HLA matching, graft manipulation and disease characteristics instead of extrapolating across these variables.
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